Total Payments
$52,829
2024 Payments
$3,395
Companies
12
Transactions
54
Medicare Patients
718
Medicare Billing
$154,232
Payment Breakdown by Category
Consulting$47,240 (89.4%)
Other$2,456 (4.6%)
Travel$2,093 (4.0%)
Food & Beverage$999.35 (1.9%)
Education$39.95 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $47,240 | 19 | 89.4% |
| Travel and Lodging | $2,093 | 11 | 4.0% |
| Honoraria | $1,306 | 1 | 2.5% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1,150 | 1 | 2.2% |
| Food and Beverage | $999.35 | 21 | 1.9% |
| Education | $39.95 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $25,770 | 26 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $8,183 | 4 | $0 (2021) |
| Lilly USA, LLC | $5,463 | 2 | $0 (2021) |
| AbbVie, Inc. | $5,313 | 11 | $0 (2018) |
| Daiichi Sankyo Inc. | $3,395 | 3 | $0 (2024) |
| PFIZER INC. | $1,600 | 1 | $0 (2022) |
| Blueprint Medicines Corporation | $1,306 | 1 | $0 (2020) |
| AI Therapeutics, Inc. | $1,125 | 1 | $0 (2022) |
| EMD Serono, Inc. | $500.00 | 1 | $0 (2021) |
| Genentech, Inc. | $139.95 | 2 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,395 | 3 | Daiichi Sankyo Inc. ($3,395) |
| 2023 | $2,055 | 1 | AstraZeneca Pharmaceuticals LP ($2,055) |
| 2022 | $2,759 | 4 | PFIZER INC. ($1,600) |
| 2021 | $12,495 | 6 | Takeda Pharmaceuticals U.S.A., Inc. ($6,533) |
| 2020 | $7,776 | 4 | AstraZeneca Pharmaceuticals LP ($4,820) |
| 2019 | $7,112 | 8 | AstraZeneca Pharmaceuticals LP ($6,972) |
| 2018 | $11,114 | 19 | AstraZeneca Pharmaceuticals LP ($5,802) |
| 2017 | $6,122 | 9 | AstraZeneca Pharmaceuticals LP ($6,122) |
All Payment Transactions
54 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/28/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $485.00 | General |
| 11/13/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,455.00 | General |
| 02/21/2024 | Daiichi Sankyo Inc. | — | Consulting Fee | Cash or cash equivalent | $1,455.00 | General |
| 10/20/2023 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $2,055.00 | General |
| Category: Oncology | ||||||
| 11/23/2022 | PFIZER INC. | XALKORI (Drug) | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| Category: ONCOLOGY | ||||||
| 09/23/2022 | Bayer HealthCare Pharmaceuticals Inc. | Vitrakvi (Drug) | Food and Beverage | In-kind items and services | $16.92 | General |
| Category: Oncology | ||||||
| 08/30/2022 | AI Therapeutics, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,125.00 | General |
| 06/07/2022 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $17.23 | General |
| Category: Hematology | ||||||
| 12/20/2021 | Lilly USA, LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,150.00 | General |
| 11/05/2021 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Consulting Fee | Cash or cash equivalent | $2,737.50 | General |
| Category: ONCOLOGY | ||||||
| 10/28/2021 | Lilly USA, LLC | — | Consulting Fee | Cash or cash equivalent | $4,312.50 | General |
| 06/22/2021 | EMD Serono, Inc. | Tepmetko (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: Oncology | ||||||
| 03/20/2021 | Takeda Pharmaceuticals U.S.A., Inc. | EXKIVITY (Drug) | Consulting Fee | Cash or cash equivalent | $1,897.50 | General |
| Category: ONCOLOGY | ||||||
| 03/20/2021 | Takeda Pharmaceuticals U.S.A., Inc. | EXKIVITY (Drug) | Consulting Fee | Cash or cash equivalent | $1,897.50 | General |
| Category: ONCOLOGY | ||||||
| 12/14/2020 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Consulting Fee | Cash or cash equivalent | $1,650.00 | General |
| Category: ONCOLOGY | ||||||
| 10/12/2020 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Consulting Fee | Cash or cash equivalent | $3,450.00 | General |
| Category: Oncology | ||||||
| 10/12/2020 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $1,370.00 | General |
| Category: Oncology | ||||||
| 08/12/2020 | Blueprint Medicines Corporation | — | Honoraria | Cash or cash equivalent | $1,306.25 | General |
| 11/08/2019 | Genentech, Inc. | TECENTRIQ (Biological) | Education | In-kind items and services | $39.95 | General |
| Category: BioOncology | ||||||
| 05/31/2019 | Genentech, Inc. | TECENTRIQ (Biological) | Food and Beverage | In-kind items and services | $100.00 | General |
| Category: BioOncology | ||||||
| 04/09/2019 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Consulting Fee | Cash or cash equivalent | $6,850.00 | General |
| Category: Oncology | ||||||
| 04/06/2019 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $44.64 | General |
| Category: Oncology | ||||||
| 04/06/2019 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $26.79 | General |
| Category: Oncology | ||||||
| 04/06/2019 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $24.11 | General |
| Category: Oncology | ||||||
| 04/06/2019 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $13.39 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 174 | 366 | $69,822 | $36,154 |
| 2022 | 3 | 186 | 451 | $85,140 | $46,559 |
| 2021 | 4 | 210 | 432 | $79,995 | $44,073 |
| 2020 | 3 | 148 | 419 | $64,100 | $27,445 |
Total Patients
718
Total Services
1,668
Medicare Billing
$154,232
Procedure Codes
13
All Medicare Procedures & Services
13 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 66 | 145 | $30,061 | $16,469 | 54.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 64 | 177 | $26,875 | $13,362 | 49.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 44 | 44 | $12,886 | $6,324 | 49.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 92 | 234 | $47,970 | $27,492 | 57.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 61 | 184 | $27,600 | $14,136 | 51.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 33 | 33 | $9,570 | $4,931 | 51.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 86 | 199 | $40,795 | $23,862 | 58.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 66 | 166 | $24,900 | $12,959 | 52.0% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 40 | 40 | $11,600 | $6,040 | 52.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 18 | 27 | $2,700 | $1,212 | 44.9% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 90 | 330 | $49,500 | $20,764 | 41.9% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 30 | 30 | $8,700 | $4,172 | 47.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 28 | 59 | $5,900 | $2,509 | 42.5% |
About Dr. Laurie Carr, M.D
Dr. Laurie Carr, M.D is a Hematology & Oncology healthcare provider based in Denver, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/01/2006. The National Provider Identifier (NPI) number assigned to this provider is 1346287968.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Laurie Carr, M.D has received a total of $52,829 in payments from pharmaceutical and medical device companies, with $3,395 received in 2024. These payments were reported across 54 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($47,240).
As a Medicare-enrolled provider, Carr has provided services to 718 Medicare beneficiaries, totaling 1,668 services with total Medicare billing of $154,232. Data is available for 4 years (2020–2023), covering 13 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Medical Oncology
- Location Denver, CO
- Active Since 06/01/2006
- Last Updated 03/07/2023
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1346287968
Products in Payments
- TAGRISSO (Drug) $16,199
- IMFINZI (Drug) $9,572
- ALUNBRIG (Drug) $4,388
- EXKIVITY (Drug) $3,795
- XALKORI (Drug) $1,600
- Tepmetko (Drug) $500.00
- TECENTRIQ (Biological) $139.95
- REBLOZYL (Biological) $17.23
- Vitrakvi (Drug) $16.92
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Denver
Dr. Yousuf Gaffar, Md, MD
Hematology & Oncology — Payments: $1.2M
Hematology & Oncology $1.2M
Robert Rifkin, Md, MD
Hematology & Oncology — Payments: $527,544
Hematology & Oncology $527,544
Dr. Jeffrey Matous, Md, MD
Hematology & Oncology — Payments: $357,552
Hematology & Oncology $357,552
Dr. Peter Mcsweeney, Md, MD
Hematology & Oncology — Payments: $151,717
Hematology & Oncology $151,717
Dr. Moses Raj, Md, MD
Hematology & Oncology — Payments: $135,648
Hematology & Oncology $135,648
Dr. Tara Gregory, M.d, M.D
Hematology & Oncology — Payments: $135,068
Hematology & Oncology $135,068